BioCentury | Jan 23, 2020
Product Development

Thirteen years from founding, Epizyme scores first FDA approval

Despite multiple setbacks over the years, Epizyme now has an approved drug on which to hang its hat and foundational hypothesis. On Thursday, its Tazverik tazemetostat became the first approved therapy to treat epithelioid sarcoma....
BC Extra | May 30, 2019
Company News

Epizyme looks to sarcoma for first approval

More than a decade after it was founded and after nearly $1 billion raised, Epizyme has submitted its first NDA to FDA for a small molecule inhibitor of an epigenetic cancer target. The company is...
BC Innovations | Sep 21, 2017
Tools & Techniques

On your marks

With less fanfare than the first two waves, a quiet rise in activity is driving a revival of interest in epigenetics, despite little progress in solving the fundamental challenges that have dogged the field from...
BioCentury | Feb 14, 2017
Emerging Company Profile

Divide or conquer

Argonaut Therapeutics Ltd. is attacking cancer by inhibiting an epigenetic regulatory protein that controls a dual role for the E2F1 pathway. By inhibiting the PRMT5 enzyme, the company’s molecules flip the pathway from growth and...
BioCentury | Jul 25, 2016
Finance

Leverage over genes

The decision to invest $55 million in a series A round for Fulcrum Therapeutics Inc. reflects Third Rock Ventures' belief that research tools including induced pluripotent stem cells, CRISPR- Cas9 gene editing and bioinformatics have...
BioCentury | Mar 21, 2016
Emerging Company Profile

Targeting toxicity

Novonco Therapeutics Inc. is developing a pipeline of targeted cancer therapies that were designed at City of Hope and University of California Irvine to be less toxic than either first-generation inhibitors, or parent molecules. Its...
BC Extra | Jan 28, 2016
Company News

Merck, CRT in deal for PRMT5 inhibitors

Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders. The inhibitors were...
BC Innovations | Jan 15, 2015
Product R&D

Epizyme's mantle piece

Epigenetic modulation notched another target last month when Epizyme Inc. announced a preclinical compound against PRMT5 - an arginine methyltransferase - that shows activity in mouse models of mantle cell lymphoma. The next step is to discover...
BC Innovations | Jul 31, 2014
Translation in Brief

Translational tidbits

Benjamin Boettner, Associate Editor, and Chris Cain, Michael J. Haas and Kai-Jye Lou, Senior Writers  Quantitative boost for CSHL The Simons Foundation has donated $50 million to Cold Spring Harbor Laboratory to establish the Simons...
BC Week In Review | Apr 28, 2014
Company News

Epizyme, GlaxoSmithKline deal

Epizyme will receive a $4 million milestone payment from GlaxoSmithKline under a 2011 deal in which the companies partnered to discover, develop and commercialize small molecule therapeutics targeting histone methyltransferases for cancer and other diseases....
Items per page:
1 - 10 of 40